SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update
by Danessa Lincoln · The Markets DailySciSparc Ltd. (NASDAQ:SPRC – Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 57,651 shares, a drop of 69.1% from the November 30th total of 186,467 shares. Based on an average daily trading volume, of 1,586,485 shares, the short-interest ratio is presently 0.0 days. Currently, 10.9% of the company’s shares are sold short. Currently, 10.9% of the company’s shares are sold short. Based on an average daily trading volume, of 1,586,485 shares, the short-interest ratio is presently 0.0 days.
Analysts Set New Price Targets
A number of brokerages recently weighed in on SPRC. Wall Street Zen upgraded shares of SciSparc to a “sell” rating in a research report on Saturday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, SciSparc currently has an average rating of “Sell”.
Check Out Our Latest Report on SPRC
SciSparc Trading Up 0.1%
Shares of SPRC opened at $1.39 on Friday. The stock has a 50 day simple moving average of $2.51 and a 200 day simple moving average of $4.29. SciSparc has a 52-week low of $1.35 and a 52-week high of $37.59.
SciSparc (NASDAQ:SPRC – Get Free Report) last announced its quarterly earnings results on Tuesday, November 18th. The company reported ($3.08) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.
SciSparc Company Profile
SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.
The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.